SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Hasan Alkomiet)
 

Sökning: WFRF:(Hasan Alkomiet) > (2013) > World Federation of...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003159naa a2200385 4500
001oai:DiVA.org:uu-278901
003SwePub
008160226s2013 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2789012 URI
0247 a https://doi.org/10.3109/15622975.2012.7397082 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Hasan, Alkomiet4 aut
2451 0a World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2 :b update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects
264 c 2012-12-06
264 1b Informa UK Limited,c 2013
338 a print2 rdacarrier
520 a These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in 2006. For this 2012 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful. They are intended to be used by all physicians diagnosing and treating people suffering from schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F) and five levels of recommendation (1-5) ( Bandelow et al. 2008a ,b, World J Biol Psychiatry 9:242, see Table 1 ). This second part of the updated guidelines covers long-term treatment as well as the management of relevant side effects. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication and other pharmacological treatment options) of adults suffering from schizophrenia.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Psykiatri0 (SwePub)302152 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Psychiatry0 (SwePub)302152 hsv//eng
7001 a Falkai, Peter4 aut
7001 a Wobrock, Thomas4 aut
7001 a Lieberman, Jeffrey4 aut
7001 a Glenthoj, Birte4 aut
7001 a Gattaz, Wagner F4 aut
7001 a Thibaut, Florence4 aut
7001 a Möller, Hans-Jürgen4 aut
7001 a von Knorring, Larsu Uppsala universitet,Psykiatri, Akademiska sjukhuset4 ctb0 (Swepub:uu)larsvon
7102 a Uppsala universitetb Psykiatri, Akademiska sjukhuset4 org
7730 t World Journal of Biological Psychiatryd : Informa UK Limitedg 14:1, s. 2-44q 14:1<2-44x 1562-2975x 1814-1412
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-278901
8564 8u https://doi.org/10.3109/15622975.2012.739708

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy